. Metastatic non-small-cell lung cancer (NSCLC) cannot be cured with systemic chemotherapy, yet clinical studies have shown a 5% benefit of postoperative (adjuvant) chemotherapy on overall survival 3 . This modest survival benefit may reflect a vulnerability of low-volume disease in the context of reduced intra-tumour heterogeneity 4 . ctDNA detection in plasma following resection of breast 5, 6 and colorectal 7 tumours has been shown to identify patients who are very likely to relapse postoperatively in advance of established clinical parameters. Identifying, monitoring and genomically characterizing residual disease following primary lung cancer surgery may improve outcomes in the adjuvant setting. This would create a therapeutic setting in which only patients who are very likely to have cancer recurrence would receive treatment and intervention could be directed to the evolving tumour subclone that seeds metastatic recurrence.
Here, we report a bespoke multiplex-PCR next-generation sequencing (NGS) approach to ctDNA profiling in the context of the prospective tumour evolutionary NSCLC TRACERx study (https://clinicaltrials. gov/ct2/show/NCT01888601). We address determinants of ctDNA detection in early-stage NSCLC and investigate the ability of ctDNA to identify and genomically characterize postoperative NSCLC relapse within a tumour phylogenetic framework.
Phylogenetic ctDNA profiling
The TRACERx study monitors the clonal evolution of NSCLC from diagnosis through to death 8, 9 . Using multi-region exome sequencing (M-seq)-derived tumour phylogenetic trees developed through prospective analysis of 100 patients from the TRACERx cohort, we conducted a phylogenetic approach to ctDNA profiling in early-stage NSCLC (Fig. 1) . Bespoke multiplex-PCR assay panels were synthesized for each patient, targeting clonal and subclonal single-nucleotide variants (SNVs) selected to track phylogenetic tumour branches in plasma (Fig. 1) . SNV detection in plasma was established through a calling algorithm using negative control samples (see Methods). Analytical validation of the multiplex-PCR NGS platform demonstrated a sensitivity of above 99% for the detection of SNVs at frequencies above 0.1% and the specificity of detecting a single SNV was 99.6% (Extended Data Fig. 1a ). At least two SNVs were detected in ctDNA from early-stage NSCLCs that had been analysed in our published discovery cohort data 10 , suggesting biological sensitivity of a two-SNV threshold for ctDNA detection. Therefore, we selected a threshold of two detected SNVs for calling a sample ctDNA-positive for validation within this study, to minimize type I errors when testing up to 30 tumour-specific SNVs per time point in a single patient (see Extended Data Fig. 1b for justification) .
Determinants of ctDNA detection in NSCLC
We sought to identify clinicopathological determinants of ctDNA detection in early-stage NSCLC by profiling preoperative plasma samples in 100 TRACERx patients. Samples from four patients could not be analysed (see cohort design in Extended Data Fig. 2a , patient characteristics in Extended Data Table 1a-c and Supplementary Table 1) . Individual assay panels were designed to target a median of 18 SNVs (range, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , comprising a median of 11 clonal SNVs (range, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] and a median of 6 subclonal SNVs (range, 0-16) per patient (Extended Data Fig. 2b, e) .
At least two SNVs were detected in ctDNA preoperatively in 46 out of 96 (48%) early-stage NSCLCs and a single SNV was detected in 12 additional cases (Fig. 2a) . Centrally reviewed pathology data revealed that ctDNA detection was associated with histological subtype: 97% (30 out of 31) of lung squamous cell carcinomas (LUSCs) and 71% (5 out of 7) of other NSCLC subtypes were ctDNA-positive, compared with 19% (11 out of 58) of lung adenocarcinomas (LUADs) (Fig. 2a) . ctDNA was detected in 94% (16 out of 17) of stage I LUSCs compared with 13% (5 out of 39) of stage I LUADs (Extended Data Fig. 3a) . Passive release of ctDNA into the circulation may be associated with necrosis 11 . As expected, LUSCs were significantly more necrotic than LUADs 12 and ctDNA-positive LUADs formed a sub-group of more necrotic tumours compared with ctDNA-negative LUADs (Extended Data Fig. 3b ). Necrosis, lymph-node involvement, lymphovascular invasion, pathologic tumour size, Ki67-labelling indices, nonadenocarcinoma histology and total cell-free DNA input predicted ctDNA detection in univariable analyses (Extended Data Fig. 3c ). Multivariable analysis revealed non-adenocarcinoma histology, the The early detection of relapse following primary surgery for non-small-cell lung cancer and the characterization of emerging subclones, which seed metastatic sites, might offer new therapeutic approaches for limiting tumour recurrence. The ability to track the evolutionary dynamics of early-stage lung cancer non-invasively in circulating tumour DNA (ctDNA ) has not yet been demonstrated. Here we use a tumour-specific phylogenetic approach to profile the ctDNA of the first 100 TRACERx (Tracking Non-Small-Cell Lung Cancer Evolution Through Therapy (Rx)) study participants, including one patient who was also recruited to the PEACE (Posthumous Evaluation of Advanced Cancer Environment) post-mortem study. We identify independent predictors of ctDNA release and analyse the tumour-volume detection limit. Through blinded profiling of postoperative plasma, we observe evidence of adjuvant chemotherapy resistance and identify patients who are very likely to experience recurrence of their lung cancer. Finally, we show that phylogenetic ctDNA profiling tracks the subclonal nature of lung cancer relapse and metastasis, providing a new approach for ctDNA-driven therapeutic studies.
presence of lymphovascular invasion and a high Ki67 proliferation index as independent predictors of ctDNA detection (Extended Data Fig. 3c ). Because 18 F-fluoro-deoxyglucose (FDG) avidity on positron emission tomography (PET) scans correlates with proliferative indices in early-stage NSCLC 13, 14 , we investigated tumour PET FDG avidity and ctDNA detection. PET FDG avidity predicted ctDNA detection (area under the curve = 0.84, P < 0.001, n = 92) (Extended Data Fig. 3d ). Within LUADs, driver events in KRAS, EGFR or TP53 were not associated with ctDNA detection (Extended Data Fig. 3e) .
We analysed the distribution of clonal and subclonal SNVs in ctDNA-positive patients. Clonal SNVs were detected in all 46 ctDNA-positive patients and a median of 94% (range, 11-100%) of clonal SNVs targeted by assay panels were detected in the ctDNA of these patients. Of 46 ctDNA-positive patients, 40 had subclonal SNVs targeted by the assay panels, and subclonal SNVs were detected in 27 (68%) of these patients. A median of 27% (range, 0-91%) of subclonal SNVs within individual assay panels were detected in ctDNA-positive patients (Fig. 2b) . The mean plasma variant allele frequency (VAF) of clonal SNVs was higher than that of subclonal SNVs (Extended Data Fig. 4a , within patient comparison, Wilcoxon signed-rank test, P < 0.001, n = 27, Supplementary Table 2) , supporting the use of clonal alterations as a more sensitive method of ctDNA detection than subclonal alterations 10, 15 . In ctDNA-positive patients, pathologic tumour size correlated with the mean plasma VAF of clonal SNVs (Spearman's ρ = 0.405, P = 0.005, n = 46, Extended Data Fig. 4b ). Computed tomography (CT) scan volumetric analyses were evaluated in 37 out of 46 ctDNA-positive patients (see Extended Data Fig. 4c ). Tumour volume from CT analyses correlated with mean clonal plasma VAF (Spearman's ρ = 0.63, P < 0.001, n = 37, Fig. 3a) . A linear relationship between log-transformed volume and log-transformed mean clonal VAF values was observed (Fig. 3a) . The line of best fit applied to the data was consistent with the line fitted to NSCLC volumetric data and ctDNA plasma VAFs that have been reported previously 16 (Extended Data Fig. 4d ). Linear modelling based on the TRACERx data predicted that a primary tumour burden of 10 cm 3 would result in a mean clonal plasma VAF of 0.1% (95% confidence interval, 0.06-0.18%) (Fig. 3b) . Tumour purity was multiplied by tumour volume to control for stromal contamination, to determine the relationship between cancer cell volume and Multi-region sequencing of NSCLC was performed as part of the TRACERx study. PCR assay panels were designed on the basis of the phylogenetic analysis, targeting clonal and subclonal SNVs to facilitate non-invasive tracking of the patient-specific tumour phylogeny. Assay panels were combined into multiplex assay pools containing primers from up to 10 patients. Cell-free DNA (cfDNA) was extracted from preand postoperative plasma samples and multiplex-PCR was performed, followed by sequencing of the amplicons. Findings were integrated with M-seq exome data to track tumour evolution. is based on the model in a, the predicted cancer cell number is based on the model in Extended Data Fig. 4e . c, Estimated effective subclone size, defined as the mean cancer cell fraction (CCF) of the subclone multiplied by tumour volume and purity, influences subclonal SNV detection. , a plasma VAF of 0.1% would correspond to a primary NSCLC malignant burden of 302 million tumour cells ( Fig. 3b and Extended Data Fig. 4f ).
To investigate predictors of subclone detection, detected subclonal SNVs were mapped back to M-seq-derived tumour phylogenetic trees. Of 57 shared subclones (identified in more than one tumour region through M-seq analysis), 35 (61%) were identified in ctDNA, compared with 26 out of 80 (33%) private subclones (detected in only a single tumour region) (Extended Data Fig. 4g ). This suggested that subclone volume influences subclonal ctDNA detection. Subclone volume was estimated on the basis of mean regional subclone cancer cell fraction and cancer cell volume. Detected subclonal SNVs mapped to subclones with significantly higher estimated volumes than did subclones containing undetected SNVs (Wilcoxon rank-sum test, P < 0.001, n = 272, Fig. 3c ) and subclone volume significantly correlated with subclonal SNV plasma VAF (Spearman's ρ = 0.53, P < 0.001, n = 109, Fig. 3d ).
Detecting and characterizing NSCLC relapse
The longitudinal phase of the study aimed to determine whether ctDNA profiling with patient-specific assay panels could detect and characterize the branched subclone(s) seeding the NSCLC relapse. Pre-and post-surgical plasma ctDNA profiling was performed blinded to relapse status in a sub-group of 24 patients (cohort characteristics, Extended Data Table 1d , e). This included relapse-free patients who had been followed up for a median of 775 days (range, 688-945 days; n = 10) and confirmed NSCLC-relapse cases (n = 14) (cohort design, Extended Data Fig. 2c ). Assay panels were redesigned in this phase of the study to target additional clonal SNVs in LUADs to attempt to improve ctDNA detection. A median of 18.5 SNVs (range, [12] [13] [14] [15] [16] [17] [18] [19] [20] were targeted by the LUSC assay panels, comprising a median of 8.5 clonal SNVs (range, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] and a median of 9.5 subclonal SNVs (range, 2-17) (Extended Data Fig. 2d, e) . A median of 28 SNVs (range, 25-30) were targeted by the LUAD assay panels, comprising a median of 20.5 clonal SNVs (range, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] and a median of 6 subclonal SNVs (range, 0-13) (Extended Data Fig. 2d , e).
Patients were followed up every three months for the first two years following study enrolment and every six months thereafter with clinical assessment and chest radiographs. At least two SNVs were detected in 13 out of 14 (93%) patients with confirmed NSCLC relapse before, or at, clinical relapse (Fig. 4a-g and Extended Data Fig. 5 ). At least two SNVs were detected in 1 out of 10 (10%) patients (CRUK0013) with no clinical evidence of NSCLC relapse ( Fig. 4h and Extended Data Fig. 6 ). Excluding a single case where no postoperative plasma was taken before clinical relapse (CRUK0041), the median interval between ctDNA detection and NSCLC relapse that was confirmed by CT imaging indicated by clinical and chest radiograph follow-up (lead time) was 70 days (range, 10-346 days). Of the 13 relapse cases, 4 exhibited lead times of more than six months (Fig. 4a-d) . In two cases ctDNA detection preceded CT imaging inconclusive for NSCLC relapse by 157 days (CRUK0004, Fig. 4b ) and 163 days (CRUK0045, Fig. 4d ). ctDNA profiling reflected adjuvant chemotherapy resistance; CRUK0080, CRUK0004 and CRUK0062 had detectable ctDNA in plasma within 30 days of surgery. The number of detectable SNVs increased in all three cases despite adjuvant chemotherapy, with disease recurring within one year after surgery (Fig. 4a-c) . In contrast, CRUK0013 had 20 SNVs detectable in ctDNA 72 h after surgery and 13 SNVs detectable before adjuvant chemoradiotherapy; 51 days after completion of adjuvant treatment and at postoperative days 457 and 667, no SNVs were detectable and the patient remains relapse-free 688 days post-surgery (Fig. 4h) . ctDNA profiling detected relapse from the central nervous system; CRUK0029 had a PET scan performed 50 days before surgery demonstrating normal cerebral appearances. ctDNA remained detectable following surgery; 54 days postoperatively the patient was diagnosed with intracerebral metastasis; no extracranial disease was evident on CT imaging (Fig. 4e) .
In cases where subclonal SNVs were detected in ctDNA postoperatively, we predicted subclonal clusters involved in the relapse process by mapping SNVs detected in plasma back to primary M-seq data (Fig. 4 and Extended Data Fig. 5b, c) . Subclonal SNVs displaying plasma VAFs similar to those of clonal SNVs from clusters confined to a single phylogenetic branch were detected postoperatively in the ctDNA of four patients who suffered NSCLC relapse (CRUK0004, CRUK0063, CRUK0065 and CRUK0044) (Fig. 4b , f, g and Extended Data Fig. 5b ). This suggested a relapse process dominated by one subclone represented in our assay panel. The subclone implicated by ctDNA as driving the relapse in the case of CRUK0004 contained an ERBB2 (also known as HER2) amplification event (more than 15 copies, triploid background), which may be targetable in NSCLC 18 ( Fig. 4b ). Relapses involving subclones from more than one phylogenetic branch were evident in patients CRUK0080, CRUK0062 ( 
Validation of phylogenetic characterization
To validate subclonal ctDNA analyses, data acquired from sequencing metastatic tissue at recurrence were integrated with M-seq primary tumour data (for biopsy details, see Supplementary Table 3) . Patient CRUK0063 suffered para-vertebral relapse of their NSCLC. Postoperative ctDNA analysis revealed the detection of the same subclonal SNV (OR5D18) on four consecutive occasions over a 231-day period (Extended Data Fig. 7a ). The OR5D18 SNV traced back to a subclonal cluster private to primary tumour region three (Fig. 5a ). CT-guided biopsy tissue was acquired from the para-vertebral metastasis at postoperative day 467. Exome sequencing of the relapse tissue revealed that the subclonal cluster in the primary tumour containing the OR5D18 SNV probably gave rise to the metastatic subclone ( Fig. 5a ), consistent with ctDNA phylogenetic characterization of the relapse. The para-vertebral biopsy contained 88 SNVs not called as present in the primary tumour, including an ARID1A stop-gain driver SNV. Re-examination of primary tumour region M-seq data with a lower SNV calling threshold revealed that 16 out of 88 SNVs, including ARID1A, were detectable in primary tumour region three, compared with a maximum of 2 out of 88 in other tumour regions (Extended Data Fig. 7b ). These data suggest that ctDNA profiling can resolve the primary tumour region from which a low-frequency metastatic subclone derives. CRUK0035 developed one adrenal and two liver metastases (Fig. 5b) . Sequencing of the metastatic liver deposit revealed that only 109 out of 149 SNVs classed as clonal in the primary tumour were detectable in the metastasis. This was suggestive of an ancestral branching event that had not been resolved through the primary M-seq analysis (Fig. 5b) . Postoperative ctDNA profiling not only identified clonal SNVs present in the liver metastasis biopsy, but also revealed SNVs representing a subclone from the primary tumour (Extended Data Fig. 7c ). This subclone was not present in the metastatic liver deposit (Fig. 5b) . These data may reflect ctDNA identified from the non-biopsied metastases, suggesting multiple metastatic events. CRUK0044 suffered a vertebral and right hilar relapse. Postoperatively, the same subclonal SNV (OR10K1) was detected in ctDNA on two occasions that were 85 days apart (Extended Data Fig. 7d ). This SNV was represented in a single subclone detected through sequencing of the hilar lymph node metastatic tissue, supporting the ctDNA findings 
TERT amp. CCNE amp. Article reSeArcH (Fig. 5c ). CRUK0041 suffered an intracerebral, hilar and subcarinal lymph node relapse. Four subclonal SNVs representing both branches of the tumour phylogenetic tree were detectable in the ctDNA at relapse. Consistent with these data, sequencing of subcarinal metastatic tissue revealed the presence of subclonal SNVs mapping to both phylogenetic branches ( Fig. 5d and Extended Data Fig. 7e ). Patient CRUK0013 had 20 SNVs detectable in ctDNA at day 3 postoperatively and 13 SNVs detectable at day 38. Following adjuvant chemoradiotherapy for lymph node metastases identified in the pathological specimen, ctDNA levels became undetectable (Fig. 4h) . Two lymph nodes involved were sampled for exome analysis together with M-seq of the primary tumour. Four subclonal SNVs detected in the ctDNA postoperatively mapped to an ancestral subclone (describing a subclone that existed during the tumour's evolution) (Extended Data Fig. 7f ). This ancestral subclone contained a KRAS amplification (more than 15 copies, triploid background) and was identified as present in the primary tumour and sampled lymph nodes by M-seq (Fig. 5e ). These data provide phylogenetic characterization of postoperative residual disease that responded to adjuvant chemoradiotherapy (Fig. 4h). ctDNA profiling in the metastatic setting Patient CRUK0063 was examined through the PEACE post-mortem study 24 h after death. M-seq data from the six post-mortem tumour regions (para-aortic, para-vertebral and lung meta stases, day 857), the para-vertebral relapse biopsy (day 467) and five primary tumour regions (day 0) were combined to infer the phylogenetic structure of this patient's NSCLC (Fig. 6a) . All seven metastatic tumour regions arose from a single ancestral subclone represented by phylogenetic cluster 8. Six metastatic regions shared a later phylogenetic origin, cluster 12 (Fig. 6b) . The single tumour region not containing phylogenetic cluster 12 was sampled from the para-aortic metastasis at autopsy and contained a private subclone represented by phylogenetic cluster 9 (Fig. 6b) .
We designed a bespoke ctDNA assay panel to retrospectively track metastatic subclonal burden. Twenty clonal SNVs and a median of 8 subclonal SNVs (range, 4-15) in each of 9 metastatic subclonal clusters were targeted by the assay panel (Extended Data Fig. 8 ). Because 103 variants per time point were profiled, SNV detection thresholds were increased to maintain platform specificity (see Methods). This resulted in a predicted false-positive rate of 0.0011, translating to a 10.7% risk of a single false-positive SNV at each time point, and a 0.5% risk of two false-positive SNVs at each time point when testing 103 SNVs.
Two clonal SNVs were detected by the 103-SNV assay panel 151 days after surgery ( Fig. 6c and Extended Data Fig. 8) ; 189 days before the time point at which ctDNA was detected using the 19-SNV assay panel in Fig. 4f . At day 242 a single subclonal SNV was detected from phylogenetic cluster 8 ( Fig. 6c and Extended Data Fig. 8) ; in the context of a 10.7% false-positive risk, a single SNV call could represent a type I error. At day 466, following clinical relapse at the thoracic paravertebral site, 18 out of 20 SNVs mapping to phylogenetic clusters (8, 11 and 12) were detected in ctDNA; these subclonal clusters were shared between six out of seven metastatic sites (Fig. 6b, c and Extended Data Fig. 8 ). Single SNVs from two private subclones (phylogenetic clusters 5 and 9) were also detectable in ctDNA at day 466 ( Fig. 6c and Extended Data Fig. 8 ). These subclones were not identified in the CT-guided para-vertebral biopsy taken at day 467 (Fig. 6b) . The mean plasma VAF of the SNVs detected in phylogenetic clusters 11, 8, 12, 9 and 5 mirrored their proximity to the clonal cluster (light blue) in the M-seqderived phylogenetic tree (Fig. 6a, c) . This suggested a tiered burden of subclonal disease concordant with M-seq phylogenetic inferences. The mean clonal VAF decreased in response to palliative radiotherapy and chemotherapy, but increased at day 767 (Fig. 6c) . Single SNVs mapping to phylogenetic clusters 5 and 9 and two SNVs mapping to phylogenetic cluster 2 were now detectable in ctDNA 90 days before death (Fig. 6a-c and Extended Data Fig. 8 ). These three phylogenetic clusters represented subclones private to the para-aortic metastases (Fig. 6a, b) . Consistent with these data, significant para-aortic progression was observed post-mortem compared with the most recent CT imaging performed 112 days before death, which showed no evidence of para-aortic disease. 
Discussion
In summary, we find predictors of ctDNA detection in early-stage NSCLC characterized by non-adenocarcinoma histology, necrosis, increased proliferative indices and lymphovascular invasion. Triplenegative breast cancers display necrosis 19 and high proliferative indices 20, 21 , and are associated with increased ctDNA levels compared with other breast cancer subtypes 6 , suggesting the possibility of extending these observations beyond NSCLC.
Tumour volume correlated with the mean plasma VAF of clonal SNVs in ctDNA-positive NSCLCs (Fig. 3a) . A primary NSCLC tumour volume of 10 cm 3 predicted a ctDNA plasma VAF of 0.1%. The sensitivity of the multiplex-PCR NGS platform was in excess of 99% at VAFs of 0.1% and above, suggesting optimum platform sensitivity with tumour burdens in excess of 10 cm -0.0033%), which is at the extreme of detection limits of current ctDNA platforms 23 . Therefore, using current technologies, the sensitivity of clonal-SNV ctDNA-directed early-NSCLC screening may be constrained by tumour size.
A limitation to targeted ctDNA profiling is cost, which is estimated at US$1,750 per patient for sequencing of a single tumour region, synthesis of a patient-specific assay panel and profiling of five plasma samples. Adjuvant platinum-based chemotherapy in NSCLC improves cure rates after surgery in only 5% of patients, and 20% of patients receiving chemotherapy experience acute toxicities 3 . There is a need to increase the efficacy of adjuvant therapy and better target its use. Bespoke ctDNA profiling can characterize the subclonal dynamics of relapsing NSCLC and identify adjuvant chemotherapy resistance. These findings indicate that drug development guided by ctDNA platforms to identify residual disease, define adjuvant treatment response and target emerging subclones before clinical recurrence in NSCLC is now feasible.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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METhOdS
Patients and samples. The cohort of 100 patients evaluated within this study comprises the first 100 patients prospectively analysed by the lung TRACERx study (https://clinicaltrials.gov/ct2/show/NCT01888601, approved by an independent Research Ethics Committee, 13/LO/1546) and mirrors the prospective 100 patient cohort described in ref. 9 .
Multi-region tumour sampling was performed as previously described 9 . Relapse tissue samples, excess to diagnostic requirements, were acquired via clinical procedures detailed in Supplementary Table 3 . For patient CRUK0063 postmortem examination was performed through the PEACE study 24 h after death (https://clinicaltrials.gov/ct2/show/NCT03004755, approved by an independent Research Ethics Committee, 13/LO/0972). Informed consent was obtained from all subjects for procedures conducted in these studies. The experiments were not randomized. Tissue microarray creation and Ki67 immunohistochemistry. Tissue micro arrays were created for 100 NSCLC cases for Ki67 + immunohistochemistry. Representative primary tumour areas were defined by examination of sections stained with haematoxylin and eosin from TRACERx cases. Two 2-mm cores were selected from different regions within each specimen and re-embedded in recipient blocks. This resulted in a tissue microarray of 200 cores with four normal lung cores as negative control. 2-5 μ m sections from tissue microarrays containing tumours were cut. Immunohistochemistry with anti-Ki67 monoclonal antibody (dilution, 1:100; clone MIB-1; DAKO Agilent Technologies LDA) was performed using BenchMark Ultra (Ventana/Roche). The percentage of Ki67 + cells was averaged across two tumour sections for each case. Detection was performed using the peroxidase-based detection reagent conjugate (OptiView DAB IHC Detection kit; Ventana). Central histopathological review. Digital images of diagnostic tumour sections from all cases were reviewed in detail centrally by at least one pathologist, and in cases of uncertainty, by two. Histological subtype, percentage of necrosis and the presence of lymphovascular invasion were all evaluated on digital images from scanned diagnostic slides blinded to the ctDNA detection status of the patient in question. Central radiology review and volume estimation. 92 out of 96 anonymized diagnostic PET-CT scans were reviewed by a nuclear medicine physician, blinded to the initial PET-CT reports. Scan images were not available in three cases (CRUK0025, CRUK0039 and CRUK0023) and in one case a preoperative PET-CT was not performed (CRUK0082). CT and PET images were matched and fused into transaxial, coronal and sagittal images and reviewed on a dedicated PET-CT software visualizer (AW 4.1/4.2 GE medical systems). The semiquantitative parameter standardized uptake value (SUV) maximum for the primary tumour mass was calculated and recorded along with the SUV max of mediastinal background uptake. The tumour-to-background ratio (TBR) was calculated on the basis of the SUV max of the tumour divided by the mediastinal background uptake 24, 25 . Tumour volume was determined on the basis of tumour CT scans. CT slices of the primary tumour were measured with 3D Slicer applying the 'lung algorithm window' settings, tumour contours were segmented on each axial CT slice. These steps were performed by an experienced resident (W.L.B.), and all contours were confirmed and edited where necessary, by a radiologist with 14 years of experience in cancer imaging (F.M.F.). Cancer cell volume was defined as tumour volume multiplied by the mean purity of the tumour on the basis of the M-seq results, purity estimates derived from the ASCAT analysis as previously described 9 . Effective subclone size was defined as the mean cancer cell fraction (CCF) across the regions of the mutation cluster multiplied by tumour volume and mean tumour purity. Tissue-exome sequencing and processing. Whole-exome sequencing was performed on DNA purified from tumour tissue and normal blood as previously described 9 , with the exception of CRUK0063_BR_T1-R1. This capture was performed according to the manufacturer's 200 ng DNA protocol (Agilent). Annotated SNV calls from primary tumours are available in ref. 9 . For this study, metastatic tissue biopsies from each of four patients (CRUK0035, CRUK0041, CRUK0044 and CRUK0063) and six metastatic samples acquired at post-mortem examination of CRUK0063 were obtained. Genomic DNA was purified from all tissue samples, and processed through the TRACERx bioinformatics pipeline as previously described 9 . Annotated SNV calls are available in Supplementary Table 4 . cfDNA extraction and quantification. Blood samples were collected in K 2 -EDTA tubes. Samples were processed within 2 h of collection by double centrifugation of the blood, first for 10 min at 1,000g, then the plasma for 10 min at 2000g. Plasma was stored in 1 ml aliquots at − 80 °C. Up to 5 ml of plasma per case was available for this study (range, 1-5 ml; median 5 ml). The entire volume of plasma was used for cfDNA extraction. cfDNA was extracted using the QIAamp Circulating Nucleic Acid kit (Qiagen) and eluted into 50 μ l DNA Suspension Buffer (Sigma). Every cfDNA sample was analysed on the Bioanalyzer High Sensitivity (Agilent) and quantified by interpolation of the mononucleosomal peak height on a calibration curve prepared from a pure cfDNA sample that was quantified previously. cfDNA library preparation. Subsequently, 40 μ l of cfDNA from each plasma sample, which is present as fragments of mononucleosomal and polynucleosomal length, was used as input into Library Prep using the Natera Library Prep kit; in two samples with extremely high cfDNA amounts, input was restricted to approximately 50,000 genome equivalents (165 ng). cfDNA was end-repaired and A-tailed. Natera custom adapters were ligated. The libraries were amplified for 15 cycles to plateau and then purified using Ampure beads following the manufacturer's protocol. The purified libraries were run on the LabChip. Successful libraries had a single peak at around 250 bp. SNV assay design and optimization. Natera's standard assay design pipeline was used to generate forward and reverse PCR primers for somatic SNVs detected in tumour samples. For every pair of primers, the probability of forming a primerdimer was calculated and assays were combined into pools such that any primer combination in a pool is not predicted to form primer-dimers. For each patient, assays were prioritized such that (1) assays covering driver SNVs had highest priority and (2) there was uniform sampling of the phylogenetic tree. For the baseline cohort, 10 balanced pools were created, each containing on average 18 assays for 10 patients' SNVs. For the longitudinal cohort, up to 10 extra assays were generated for samples. For patient CRUK0063 post-mortem analysis, new assays were designed on the basis of the M-seq of the metastatic biopsy retrieved on day 467 and of metastatic lesions collected post-mortem. A total of 103 new assays were designed compared with the 19 that were based on the primary tumour alone. Primer details are available in Supplementary SNV assays were ordered from IDT. Each pool was optimized by running the multiplex-PCR and sequencing protocol using one plasma cfDNA library from a healthy subject. For optimization, PCR parameters (primer concentration and annealing temperature) that yielded the best percentage of on-target reads, depth-of-read uniformity (measured as the ratio of the 80th percentile to the 20th percentile), and number of drop-out assays (defined as assays with < 1,000 reads) were determined by sequencing. The PCR conditions that yield the best percentage of on-target reads, depth-of-read uniformity, and the lowest number of drop-outs were determined. For all pools, the optimal conditions were 10 nM primers and 60 °C or 62.5 °C annealing temperatures. Primer pairs contributing to dimer formation were removed from each final pool. Analytical validation. Synthetic spikes representing twenty SNVs that were randomly selected from primer assay pool 1 were designed and synthesized (IDT) as 160-bp oligos with the respective SNV placed in the middle (position 80). These synthetic spikes were mixed at equimolar ratios and used to prepare a library. This library was titrated into a library prepared from mononucleosomal DNA (10,000 copies) from a normal cell line (AG16778 from Coriell). The library of 20 synthetic spikes was titrated into the mononucleosomal DNA library at 2.5%, 0.5%, 0.25%, 0.1%, 0.05% and 0% (each in triplicate), and 0.01%, 0.005% and 0.001% (each in quadruplicate). Because preparing spiked samples at such low levels is either subject to sampling noise (0.01% spikes into 10,000 genomic copies background is equivalent to one mutant copy), or is not possible (at levels less than 0.01%), samples were mixed as libraries. Following library mixing and sequencing, data was analysed to detect all the targets in assay pool 1 using the same parameters as used for the patient samples.
The measured VAF of each spike for the samples with 2.5% nominal input was used to calculate an input correction factor (measured VAF/2.5%). This correction factor was applied to the other inputs of the corresponding spike titration series. The measured VAF differed from the nominal input most likely because the mononucleosomal fragmentation pattern is not entirely random. Because of this, the actual input levels differ from the nominal input levels. Therefore, analytical sensitivity and specificity were measured on the basis of the corrected input intervals (see Extended Data Fig. 1a) . Plasma SNV multiplex-PCR NGS workflow. The library material from each plasma sample was used as input into the multiplex-PCR (mPCR) using the relevant assay pool and an optimized plasma mPCR protocol. Optimal mPCR conditions were as previously described 10 . Each PCR assay pool was used to amplify the SNV targets from the 10 corresponding samples and 20 negative control samples (plasma libraries prepared from healthy subjects; BioMed IRB 601-01 and E&I West Coast Board IRB00007807, study 13090-01A and 13090-04A). The mPCR products were barcoded in a separate PCR step. Each amplicon pool was sequenced on one Illumina HiSeq 2500 Rapid Run with 50 cycles paired-end reads using the Illumina Paired End v1 kit with an average target read depth of around 40,000 per assay.
Bioinformatics pipeline. All the paired-end reads were merged using Pear 26 . Merged reads were mapped to the hg19 reference genome with Novoalign version 2.3.4 (http://www.novocraft.com/) and sorted and indexed using SAMtools 27 . Bases that did not match in forward and reverse reads or that have Phred quality score < 20 were filtered out to minimize sequencing errors in subsequent steps. Merged reads with mapping quality > 30 and at most one mismatch under the sequence of the primers were marked as on-target. Targets with < 1,000 reads were considered to have failed and were filtered from further analyses. Quality control was performed using an in-house program checking for a wide list of statistics per sample that included total numbers of reads, mapped reads, on-target reads, number of failed targets and average error rate. Plasma SNV calling. For each target SNV a position-specific error model was built (see Methods section 'SNV calling algorithm'). Samples with high plasma VAF (> 20%) among the putative negatives were considered to have possible germline mutations and were excluded from the error model. A confidence score was calculated for each target SNV on the basis of the error model and a positive plasma SNV call was made if the confidence score passed a threshold of 95% for transitions and 98% for transversions. There was no difference in read depth between called and not called SNVs (Extended Data Fig. 1c) .
Because the post-mortem analysis of CRUK0063 involved a larger number of target SNVs per time point being analysed (103 versus 19 targets in previous samples), updated calling thresholds were applied to control for false positives. The new updated thresholds were chosen such that the average number of false positives in the 30 negative samples in the run becomes around 1 per sample. All multiplex-PCR NGS ctDNA SNV assays with confidence score data are available in Supplementary Table 5 (baseline, preoperative cohort assays), Supplementary Table 6 (longitudinal assays), and Supplementary Table 7 (extended longitudinal assays for CRUK0063). SNV calling algorithm. The PCR process was modelled as a stochastic process, estimating the error parameters using a set of 28-30 control plasma samples and making the final SNV calls on the target cancer samples. For each target SNV, we built a target-specific background-error model by estimating the following para meters from the control samples: PCR efficiency (p), probability that each molecule is replicated in a PCR cycle; error rate (p e ), error rate per cycle for mutation type e (for example, wild-type allele A to mutant allele G); initial number of molecules (X 0 ).
The target-specific error propagation model was used to characterize the distribution of error molecules. As a molecule is replicated over the course of the PCR process, more errors occur. If an error occurs in cycle i and there are X i wild-type molecules in the system, that error molecule is duplicated in next cycle with probability p, and new error molecules are produced from the wild-type background molecules according to a binomial process, B(X i , p e ). Using a recursive relation, we computed the mean and variance of the number of total molecules X n and number of error molecules E n after n PCR cycles.
Algorithm steps are as follows. (1) Estimate the PCR efficiency and per-cycle error rate using the normal control samples. (2) Using the efficiency estimate, compute the starting number of molecules in the test set. (3) Use the starting number of molecules and the prior efficiency distribution from the training set to estimate the PCR efficiency in the test sample. (4) For a range of potential real mutant fraction values θ between 0 and 1 (we used 0.15 as upper bound), estimate the mean and variance for the total number of molecules, background error molecules and real mutation molecules using the described error propagation model and parameters estimated in steps (1) Data Table 2a, b and Supplementary Table 8 ). 20 ng of isolated cfDNA was used for library preparation using the Oncomine Lung cfDNA assay (ThermoFisher Scientific), according to the manufacturer's instructions. Automated template preparation and chip loading was conducted on the Ion Chef instrument using the Ion 520 & Ion 530 Kit-Chef (ThermoFisher Scientific). Ultimately, samples were sequenced on Ion 530 chips using the Ion S5 System (ThermoFisher Scientific). Sequencing data was accessed on the Torrent suite version 5.2.2. Reads were aligned against the human genome (hg19) using Alignment version 4.0-r77189, and variants were called using the coverage Analysis version 4.0-r77897 plugin. All 18 bespoke-panel ctDNA-negative patients had no tumour SNVs detectable in plasma preoperatively by the generic panel, supporting biological specificity of the bespoke targeted approach, 7 out of 10 bespoke-panel ctDNA-positive patients had tumour SNVs detected in plasma by the generic panel (Extended Data  Table 2a , b). SNVs detected by the hotspot panel not identified by M-seq are displayed in Extended Data Table 2c .
Processing and phylogenetic analysis of relapse and primary tumour multi-region whole-exome data. Biopsies from multiple regions from the primary tumour (n = 327), metastatic biopsies (n = 4) and matching blood germline samples (n = 100) were subjected to multi-region whole exome sequencing and analysis including estimation of copy number, purity and ploidy, and phylogenetic tree construction as previously described 9 .
In brief, phylogenetic analysis was performed on the basis of the CCF determined for SNVs and clustered across tumour regions using a modified version of Pyclone 9 into clusters with similar CCF values, filtered and processed as previously described 9 . Mutation clusters are assumed to represent tumour subclones, either current or ancestral, and are used as input for construction of the phylogenetic relationship. Phylogenetic trees were primarily constructed using the published tool CITUP (0.1.0) 28 . However, in a small number of cases, including all relapse/autopsy cases, manual tree construction was required and performed as previously described 9 . Complete details of primary tumour tree construction can be found in ref. 9 . Relapse tree construction was performed as follows. CRUK0063: clustering was performed twice, once across five primary tumour regions and once across five primary, one relapse, and six autopsy regions. To ensure consistency, when deriving a phylogenetic tree based on all tumour regions, for CCF clusters based on clustering, only the primary tumour regions were maintained for mutations not involved in metastatic relapse. A phylogenetic tree was constructed based on 17 mutation clusters. CRUK0035: clustering primary tumour regions with the relapse region revealed one cluster private to the relapse, and one cluster shared with the relapse and all other regions. CRUK0044: clustering primary tumour regions with the relapse region revealed a cluster private to the relapse, descended from a cluster private to region 1 in the primary tumour. CRUK0041: clustering primary tumour regions with the relapse region revealed cluster 4 as private to the relapse. This cluster must have evolved from cluster 3 only found in the relapse and in region 4. A private cluster 6 in region 4 must have evolved from cluster 4. However, this conflicts with clusters 2 and 5, found in the relapse and regions 1-3, but not region 4. This can be reconciled by assuming a polyclonal relapse, seeded primarily from regions 1-3, but with some contribution from cluster 3, private to region 4. Cluster data are available in Supplementary Table 4 under 'PyClonePhyloCluster' . Statistical data analysis. No statistical methods were used to predetermine sample size. Analysis was performed in the R statistical environment version 3.2.3 and SPSS version 24. All statistical tests were two-sided, unless expressly stated. Multivariate logistic regression used detection of ctDNA (the dependent variable) classified as detection of two or more patient-specific variants in ctDNA and the covariates listed in Supplementary Table 1. All predictors were entered simultaneously into the regression. All continuous independent variables were found to be linearly related to the logit of the dependent variable (assessed using the BoxTidwell procedure). The logistic regression model was statistically significant, χ 10 2 = 81.35, P < 0.001 and the Hosmer-Lemeshow P value was 0.9858, indicating that the model was not a poor fit. To determine the ability of PET TBR to predict whether or not tumour ctDNA was identified in plasma, PET TBR estimates were analysed by receiver operating characteristic (ROC) curve analysis against binary detection of ctDNA in plasma at baseline on the basis of at least two variants detected; significance was based on theWilcoxon rank-sum test. For analysis involving longitudinally detected variants (Fig. 4 and Extended Data Fig. 5 ), only subclonal variants from Pyclone clusters present in phylogenetic trees were displayed; this did not affect ctDNA detection status of any time points. In non-relapse cases presented in Extended Data Fig. 6 all detected subclonal SNVs were plotted. To determine the relationship between tumour volume and ctDNA VAF, ctDNA assays against clonal SNVs were selected. For each patient, the mean ctDNA VAF of the clonal SNVs was determined as baseline for 38 out of 46 patients with at least two SNVs detected in plasma. As detailed in Extended Data Fig. 4c, 9 out of 46 patients were not included in the analysis: CRUK0036 had no preoperative CT scan available; CRUK0087 and CRUK0096 had a large cavity inside the primary cancer; CRUK0099 had a collapsed lung making volume assessment inaccurate; CRUK0100, CRUK0077 and CRUK0052 had a CT slice spacing of > 5 mm (CT slice spacing for all volumetric analyses detailed in Supplementary Table 1) ; and finally CRUK0088 and CRUK0091 had a total tumour volume of < 3.5 cm 3 . Linear regression was performed on logtransformed mean VAF and tumour volume. The log transformation was justified as it symmetrized the residuals in the model. An independent analysis was performed where tumour volume was multiplied with tumour purity to estimate the cancer cell volume. The same log transformation and analysis was applied to Article reSeArcH data acquired from ref. 16 , where ctDNA VAF was determined based on CAPPseq analysis with matched tumour volume data available. To analyse clone size versus ctDNA VAF for subclonal SNVs, the mean CCF of the mutations within a subclonal mutation cluster was multiplied with tumour volume, and as a second independent analysis, with tumour purity. Data availability. Sequence data has been deposited at the European Genomephenome Archive (EGA), which is hosted by the The European Bioinformatics Institute (EBI) and the Centre for Genomic Regulation (CRG), under accession numbers EGAS00001002247 (primary tumour data) and EGAS00001002415 (metastatic tumour data). Further information about EGA can be found at https://ega-archive.org (the European Genome-phenome Archive of human data consented for biomedical research).
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